MIRA Historical Balance Sheet

MIRA Stock

1.06 0.04 3.64%

Trend analysis of MIRA Pharmaceuticals, Common balance sheet accounts such as Total Current Liabilities of 843.8 K provides information on MIRA Pharmaceuticals,'s total assets, liabilities, and equity, which is the actual value of MIRA Pharmaceuticals, to its prevalent stockholders. By breaking down trends over time using MIRA Pharmaceuticals, balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining MIRA Pharmaceuticals, latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether MIRA Pharmaceuticals, is a good buy for the upcoming year.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MIRA Pharmaceuticals, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

About MIRA Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of MIRA Pharmaceuticals, at a specified time, usually calculated after every quarter, six months, or one year. MIRA Pharmaceuticals, Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of MIRA Pharmaceuticals, and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which MIRA currently owns. An asset can also be divided into two categories, current and non-current.

MIRA Pharmaceuticals, Balance Sheet Chart

At present, MIRA Pharmaceuticals,'s Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 843.8 K, whereas Total Assets are forecasted to decline to about 2.7 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Total Assets

Total assets refers to the total amount of MIRA Pharmaceuticals, assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in MIRA Pharmaceuticals, books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on MIRA Pharmaceuticals, balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of MIRA Pharmaceuticals, Common are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from MIRA Pharmaceuticals,'s balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into MIRA Pharmaceuticals, current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MIRA Pharmaceuticals, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	491.2K	5.1K	4.6K	4.3K
Total Assets	858.1K	4.9M	2.9M	2.7M

Short Long Term Debt Total Total Assets

MIRA Pharmaceuticals, balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Accounts Payable	Other Current Assets	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Property Plant Equipment
Total Assets		-0.07	0.48	0.66	0.97	0.12	-0.98	-0.78	1.0	0.4	0.51	0.41	1.0	0.8	0.81	0.64	1.0	-0.08	-0.76	-0.73	0.42	-0.72	-0.71	0.59	-0.72	-0.42
Short Long Term Debt Total	-0.07		-0.3	0.61	-0.29	0.32	0.25	0.24	-0.15	0.85	0.46	0.4	-0.15	-0.38	-0.26	0.62	-0.14	0.99	0.55	0.65	0.12	-0.08	-0.09	-0.21	-0.08	0.33
Other Current Liab	0.48	-0.3		0.45	0.42	-0.28	-0.56	-0.86	0.49	-0.08	-0.04	-0.08	0.49	0.42	0.85	0.44	0.48	-0.34	-0.77	-0.72	-0.45	-0.68	-0.64	0.93	-0.67	-0.95
Total Current Liabilities	0.66	0.61	0.45		0.45	0.16	-0.55	-0.59	0.6	0.81	0.58	0.46	0.6	0.32	0.59	1.0	0.61	0.58	-0.31	-0.17	0.13	-0.73	-0.72	0.53	-0.73	-0.39
Total Stockholder Equity	0.97	-0.29	0.42	0.45		0.09	-0.98	-0.72	0.98	0.2	0.42	0.33	0.98	0.84	0.76	0.42	0.98	-0.29	-0.8	-0.81	0.45	-0.6	-0.6	0.52	-0.6	-0.37
Net Tangible Assets	0.12	0.32	-0.28	0.16	0.09		-0.04	0.38	0.09	0.59	0.88	0.94	0.09	-0.33	-0.33	0.15	0.08	0.42	0.41	0.28	-0.15	0.47	0.47	-0.37	0.47	0.27
Net Debt	-0.98	0.25	-0.56	-0.55	-0.98	-0.04		0.83	-0.99	-0.23	-0.4	-0.31	-0.99	-0.85	-0.86	-0.53	-0.99	0.26	0.85	0.83	-0.35	0.7	0.69	-0.63	0.7	0.52
Retained Earnings	-0.78	0.24	-0.86	-0.59	-0.72	0.38	0.83		-0.79	-0.05	-0.01	0.09	-0.79	-0.75	-1.0	-0.58	-0.79	0.29	0.93	0.84	-0.07	0.92	0.9	-0.93	0.91	0.79
Cash	1.0	-0.15	0.49	0.6	0.98	0.09	-0.99	-0.79		0.32	0.46	0.36	1.0	0.81	0.82	0.57	1.0	-0.16	-0.8	-0.78	0.41	-0.7	-0.7	0.6	-0.7	-0.42
Non Current Assets Total	0.4	0.85	-0.08	0.81	0.2	0.59	-0.23	-0.05	0.32		0.83	0.76	0.32	-0.07	0.06	0.81	0.33	0.87	0.22	0.28	0.19	-0.24	-0.25	0.0	-0.24	0.12
Non Currrent Assets Other	0.51	0.46	-0.04	0.58	0.42	0.88	-0.4	-0.01	0.46	0.83		0.99	0.46	0.0	0.06	0.56	0.46	0.53	0.1	0.04	0.07	0.01	0.01	-0.05	0.01	0.07
Other Assets	0.41	0.4	-0.08	0.46	0.33	0.94	-0.31	0.09	0.36	0.76	0.99		0.36	-0.11	-0.04	0.44	0.36	0.48	0.18	0.09	-0.04	0.15	0.15	-0.12	0.15	0.09
Cash And Short Term Investments	1.0	-0.15	0.49	0.6	0.98	0.09	-0.99	-0.79	1.0	0.32	0.46	0.36		0.81	0.82	0.57	1.0	-0.16	-0.8	-0.78	0.41	-0.7	-0.7	0.6	-0.7	-0.42
Common Stock Shares Outstanding	0.8	-0.38	0.42	0.32	0.84	-0.33	-0.85	-0.75	0.81	-0.07	0.0	-0.11	0.81		0.79	0.31	0.82	-0.42	-0.86	-0.75	0.54	-0.71	-0.67	0.47	-0.71	-0.48
Other Stockholder Equity	0.81	-0.26	0.85	0.59	0.76	-0.33	-0.86	-1.0	0.82	0.06	0.06	-0.04	0.82	0.79		0.58	0.82	-0.31	-0.94	-0.85	0.09	-0.9	-0.88	0.9	-0.9	-0.8
Total Liab	0.64	0.62	0.44	1.0	0.42	0.15	-0.53	-0.58	0.57	0.81	0.56	0.44	0.57	0.31	0.58		0.59	0.59	-0.29	-0.15	0.13	-0.73	-0.72	0.52	-0.73	-0.38
Total Current Assets	1.0	-0.14	0.48	0.61	0.98	0.08	-0.99	-0.79	1.0	0.33	0.46	0.36	1.0	0.82	0.82	0.59		-0.15	-0.79	-0.77	0.43	-0.71	-0.71	0.6	-0.71	-0.42
Short Term Debt	-0.08	0.99	-0.34	0.58	-0.29	0.42	0.26	0.29	-0.16	0.87	0.53	0.48	-0.16	-0.42	-0.31	0.59	-0.15		0.59	0.68	0.1	0.0	-0.02	-0.26	0.0	0.36
Common Stock	-0.76	0.55	-0.77	-0.31	-0.8	0.41	0.85	0.93	-0.8	0.22	0.1	0.18	-0.8	-0.86	-0.94	-0.29	-0.79	0.59		0.96	-0.15	0.77	0.75	-0.81	0.76	0.73
Accounts Payable	-0.73	0.65	-0.72	-0.17	-0.81	0.28	0.83	0.84	-0.78	0.28	0.04	0.09	-0.78	-0.75	-0.85	-0.15	-0.77	0.68	0.96		-0.08	0.61	0.61	-0.78	0.6	0.63
Other Current Assets	0.42	0.12	-0.45	0.13	0.45	-0.15	-0.35	-0.07	0.41	0.19	0.07	-0.04	0.41	0.54	0.09	0.13	0.43	0.1	-0.15	-0.08		-0.27	-0.3	-0.21	-0.29	0.44
Net Invested Capital	-0.72	-0.08	-0.68	-0.73	-0.6	0.47	0.7	0.92	-0.7	-0.24	0.01	0.15	-0.7	-0.71	-0.9	-0.73	-0.71	0.0	0.77	0.61	-0.27		0.99	-0.82	1.0	0.61
Short Long Term Debt	-0.71	-0.09	-0.64	-0.72	-0.6	0.47	0.69	0.9	-0.7	-0.25	0.01	0.15	-0.7	-0.67	-0.88	-0.72	-0.71	-0.02	0.75	0.61	-0.3	0.99		-0.83	0.99	0.53
Capital Stock	0.59	-0.21	0.93	0.53	0.52	-0.37	-0.63	-0.93	0.6	0.0	-0.05	-0.12	0.6	0.47	0.9	0.52	0.6	-0.26	-0.81	-0.78	-0.21	-0.82	-0.83		-0.81	-0.79
Net Working Capital	-0.72	-0.08	-0.67	-0.73	-0.6	0.47	0.7	0.91	-0.7	-0.24	0.01	0.15	-0.7	-0.71	-0.9	-0.73	-0.71	0.0	0.76	0.6	-0.29	1.0	0.99	-0.81		0.6
Property Plant Equipment	-0.42	0.33	-0.95	-0.39	-0.37	0.27	0.52	0.79	-0.42	0.12	0.07	0.09	-0.42	-0.48	-0.8	-0.38	-0.42	0.36	0.73	0.63	0.44	0.61	0.53	-0.79	0.6

Click cells to compare fundamentals

MIRA Pharmaceuticals, Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether MIRA Pharmaceuticals, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MIRA Pharmaceuticals,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mira Pharmaceuticals, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mira Pharmaceuticals, Common Stock:

How To Invest In MIRA

Details

Is MIRA Stock a good investment?

Details

What is MIRA Pharmaceuticals,'s Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MIRA Pharmaceuticals,. If investors know MIRA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MIRA Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.55)

Return On Assets

(0.81)

Return On Equity

(1.92)

The market value of MIRA Pharmaceuticals, is measured differently than its book value, which is the value of MIRA that is recorded on the company's balance sheet. Investors also form their own opinion of MIRA Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is MIRA Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MIRA Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect MIRA Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between MIRA Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if MIRA Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MIRA Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

MIRA Historical Balance Sheet

About MIRA Balance Sheet Analysis

MIRA Pharmaceuticals, Balance Sheet Chart

Total Assets

Total Current Liabilities

MIRA Pharmaceuticals, balance sheet Correlations

MIRA Pharmaceuticals, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash

Other Stockholder Equity	- 1.0	Retained Earnings
Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Net Debt	- 0.98	Total Stockholder Equity
Net Debt	- 0.98	Total Assets